stephen B Hanauer

Grants

Grants per year 2014 2014 2015 2016 2017 2018 2019 2028

• 9 Active
• 55 Finished

Grants per year

Search results

• Finished

  Prot#GS-US-419-4015: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD)

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., Gilead Sciences, Inc

  5/30/18 → 5/30/21

  Project: Research project

• Prot#GS-US-419-4016: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., Gilead Sciences, Inc

  5/30/18 → 5/31/22

  Project: Research project

• Prot#APD371-004: A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects with Crohn’s Disease Experiencing Abdominal Pain

  Hanauer, S. B. (PD/PI)

  PPD Investigator Services, LLC, Arena Pharmaceuticals, Inc.

  3/29/18 → 3/29/21

  Project: Research project

• Prot# GS-US-418-3899: A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis

  Hanauer, S. B. (PD/PI)

  PRA Health Sciences, Gilead Sciences, Inc

  1/17/18 → 1/17/21

  Project: Research project

• GS-US-419-3896: A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease

  Hanauer, S. B. (PD/PI)

  PRA Health Sciences, Gilead Sciences, Inc

  1/17/18 → 1/31/25

  Project: Research project

• Prot#GED-0301-CD-004:A Phase 3, Long-term Active Treatment Extension Study of Mongersen (GED-0301) in Subjects with Crohn’s Disease

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., Celgene Corporation

  12/22/17 → 12/22/18

  Project: Research project

• Prot#GED-0301-CD-003:A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects with Active Crohn’s Disease

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., Celgene Corporation

  12/13/17 → 12/13/18

  Project: Research project

• Defining Molecular Pathways in Inflammatory Bowel Disease (B16-147)

  Hanauer, S. B. (PD/PI)

  AbbVie Inc.

  12/11/17 → 12/31/21

  Project: Research project

  • Inflammatory Bowel Disease 100%
  • Molecular Pathways 100%
  • Crohn's Colitis 100%
  • RNA Sequencing (RNA-seq) 66%
  • Northwestern University 66%

• Prot# V56502: A Phase 2 Study to Investigate the Efficacy, Safety, and Tolerability of Six Weeks Treatment with V565 in Subjects with Active Crohn’s Disease

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., VHsquared Ltd.

  9/22/17 → 9/22/20

  Project: Research project

• Assessment of Subclinical Inflammation in Patients with Inflammatory Bowel Disease who use Cannabis

  Hanauer, S. B. (PD/PI)

  Northwestern Memorial Hospital, Digestive Health Foundation

  9/1/17 → 8/31/19

  Project: Research project

  • Subclinical Inflammation 100%
  • Inflammatory Bowel 100%
  • Cannabis 100%
  • Cannabis Use 100%
  • Inflammation 100%

• Prot#GS-US-419-3895: Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

  Hanauer, S. B. (PD/PI)

  Gilead Sciences, Inc

  7/19/17 → 7/19/24

  Project: Research project

• Prot# GS-US-418-3898: Combined Phase 2b/3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Coliti

  Hanauer, S. B. (PD/PI)

  PRA Health Sciences, Gilead Sciences, Inc

  7/19/17 → 7/19/20

  Project: Research project

• Prot: BI 695501 versus Humira® in Patients with Active Crohn’s Disease: A Randomized, Double-Blind, Multicenter, Parallel Group, Non-Inferiority Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.

  6/30/17 → 6/30/20

  Project: Research project

• Prot# I6T-MC-AMAC: A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis

  Hanauer, S. B. (PD/PI)

  Lilly USA, LLC

  5/23/17 → 12/5/17

  Project: Research project

• DINE-CD Randomized, Multicenter, Comparative Effectiveness Trial of Diets to Induce Remission in Patients with Crohn’s Disease

  Hanauer, S. B. (PD/PI)

  University of Pennsylvania, Patient-Centered Outcomes Research Institute

  3/1/17 → 7/31/20

  Project: Research project

• Prot# 13.06.CLI: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness of a Nutritional Intervention in Improving the Intestinal Mucosal Health Status in Subjects with Crohn’s Disease (CD) Receiving Induction Anti-TNF Therapy

  Hanauer, S. B. (PD/PI)

  Robarts Clinical Trials Inc, Nestec Ltd.

  2/24/17 → 2/24/20

  Project: Research project

• Prot# GED-0301-CD-002: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects with Active Crohn’s Disease

  Hanauer, S. B. (PD/PI)

  Celgene Corporation

  2/22/17 → 2/22/20

  Project: Research project

• Prot# D5170C00002: A Phase 2b Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Ther

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., MedImmune, LLC

  11/7/16 → 11/7/19

  Project: Research project

• Prot #RPC01-3102: A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., Celgene International II Sàrl

  11/2/16 → 11/2/22

  Project: Research project

• (Itishree Trivedi, MD) Adaptation of a Quality Toolbox for Integration of Young Adults with IBD in Adult-Centered Care

  Hanauer, S. B. (PD/PI) & Holl, J. L. (PD/PI)

  American College of Gastroenterology

  7/1/16 → 6/30/18

  Project: Research project

  • Centre Care 100%
  • Older Adults 100%
  • Inflammatory Bowel Disease 100%
  • Adaptation 100%
  • Pediatrics 30%

• Prot #ACH-UCP-301: A Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects with Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis

  Hanauer, S. B. (PD/PI)

  SynteractHCR, Inc., Atlantic Pharmaceuticals Limited

  6/21/16 → 6/21/19

  Project: Research project

• Prot #RPC01-3101: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., Celgene International II Sàrl

  5/3/16 → 5/3/21

  Project: Research project

• Prot #GS-US-326-1100: A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis

  Hanauer, S. B. (PD/PI)

  ICON Clinical Research, LLC, Gilead Sciences, Inc

  4/15/16 → 4/15/19

  Project: Research project

• Prot #GA29145: An Open-Label Extension and Safety Monitoring Study of Patients With Moderately to Severely Active Crohn’s Disease Previously Enrolled In The Etrolizumab Phase III Protocol GA29144

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., Genentech, Inc

  4/12/16 → 7/31/23

  Project: Research project

• Prot #GS-US-395-1663: A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Crohn's Disease

  Hanauer, S. B. (PD/PI)

  Gilead Sciences, Inc

  2/26/16 → 2/26/19

  Project: Research project